What is Imagion Biosystems?
Imagion Biosystems is a clinical-stage medical imaging company focused on advancing cancer diagnostics through its proprietary molecular MRI technology. The company's MagSense platform utilizes bio-safe magnetic nanoparticles to identify cancer biomarkers, enabling the detection of tumors as small as 12 mm. This innovative approach seeks to improve diagnostic accuracy for various cancers, including HER2-positive breast cancer, prostate cancer, and ovarian cancer, potentially reducing the need for invasive procedures. The company is currently preparing for Phase II clinical trials to further validate its imaging agents.
How much funding has Imagion Biosystems raised?
Imagion Biosystems has raised a total of $5.6M across 2 funding rounds:
Other Financing Round
$3M
Stock/Share Issuance
$2.6M
Other Financing Round (2024): $3M with participation from CPS Capital
Stock/Share Issuance (2026): $2.6M, investors not publicly disclosed
Key Investors in Imagion Biosystems
CPS Capital
CPS Capital is a private equity investment firm specializing in small-cap opportunities, focusing on founder-owned businesses. They partner closely with management teams to foster long-term growth and utilize unique transaction structures.
What's next for Imagion Biosystems?
With the recent major strategic investment, Imagion Biosystems is poised to advance its clinical development pipeline, particularly its Phase II trials. This infusion of capital will likely accelerate the validation and potential commercialization of the MagSense technology. The company's focus on early and precise cancer detection aligns with a growing demand for less invasive and more accurate diagnostic tools, positioning Imagion Biosystems for significant growth in the medical imaging market. Future funding rounds may be anticipated as the company progresses through clinical stages and seeks regulatory approvals.
See full Imagion Biosystems company page
